Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07077395 · ClinicalTrials.gov registry record · Phase 2
Finding Links Between Hot flASHes and CardioVascular Disease
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT07077395: Recruiting Phase 2 study, sponsored by Massachusetts General Hospital.
NCT07077395 is a Phase 2 study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07077395, a Phase 2 study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Interventions
- DRUG placebo
- DRUG elinzanetant - reference formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07077395
The ClinicalTrials.gov registry entry for NCT07077395 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT07077395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07077395 about?
NCT07077395 is a clinical study titled "Finding Links Between Hot flASHes and CardioVascular Disease". The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood v...
What is the current status of trial NCT07077395?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-03-01. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07077395?
The interventions under investigation include: placebo (DRUG), elinzanetant - reference formulation (DRUG).
Who is sponsoring clinical trial NCT07077395?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.